122 related articles for article (PubMed ID: 31278009)
1. Mutations in TP53, ZNF750, and RB1 typify ocular sebaceous carcinoma.
Bao Y; Selfridge JE; Wang J; Zhao Y; Cui J; Guda K; Wang Z; Zhu Y
J Genet Genomics; 2019 Jun; 46(6):315-318. PubMed ID: 31278009
[No Abstract] [Full Text] [Related]
2. NGS Analysis Confirms Common
Peterson C; Moore R; Hicks JL; Morsberger LA; De Marzo AM; Zou Y; Eberhart CG; Campbell AA
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445161
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis.
Xu S; Moss TJ; Laura Rubin M; Ning J; Eterovic K; Yu H; Jia R; Fan X; Tetzlaff MT; Esmaeli B
Mod Pathol; 2020 Jul; 33(7):1256-1263. PubMed ID: 31937901
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
5. Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations.
Tetzlaff MT; Curry JL; Ning J; Sagiv O; Kandl TL; Peng B; Bell D; Routbort M; Hudgens CW; Ivan D; Kim TB; Chen K; Eterovic AK; Shaw K; Prieto VG; Yemelyanova A; Esmaeli B
Clin Cancer Res; 2019 Feb; 25(4):1280-1290. PubMed ID: 30420449
[TBL] [Abstract][Full Text] [Related]
6. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
[TBL] [Abstract][Full Text] [Related]
7. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
8. Impact of RB1 gene mutation type in retinoblastoma patients on clinical presentation and management outcome.
Mehyar M; Mosallam M; Tbakhi A; Saab A; Sultan I; Deebajah R; Jaradat I; AlJabari R; Mohammad M; AlNawaiseh I; Al-Hussaini M; Yousef YA
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):152-159. PubMed ID: 32222358
[TBL] [Abstract][Full Text] [Related]
9. Genetic Alterations of Both MEN1/ATRX and TP53/RB1 in Pancreatic Neuroendocrine Neoplasms.
Zhang MY; He D; Zhang S; Liu JY
Pancreas; 2022 Jul; 51(6):e91-e93. PubMed ID: 36206476
[No Abstract] [Full Text] [Related]
10. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
11. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
12. Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival.
Alessandrino F; Williams K; Nassar AH; Gujrathi R; Silverman SG; Sonpavde G; Shinagare AB
Radiology; 2020 Jun; 295(3):572-580. PubMed ID: 32228295
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnosis in patients with retinoblastoma: Report of a series of cases.
Ossandón D; Zanolli M; López JP; Benavides F; Pérez V; Repetto GM
Arch Soc Esp Oftalmol; 2016 Aug; 91(8):379-84. PubMed ID: 27021801
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Schwermer M; Hiber M; Dreesmann S; Rieb A; Theißen J; Herold T; Schramm A; Temming P; Steenpass L
Exp Cell Res; 2019 Feb; 375(2):92-99. PubMed ID: 30584916
[TBL] [Abstract][Full Text] [Related]
15. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer.
El Shamieh S; Saleh F; Assaad S; Farhat F
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145688
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
Bousquet M; Noirot C; Accadbled F; Sales de Gauzy J; Castex MP; Brousset P; Gomez-Brouchet A
Ann Oncol; 2016 Apr; 27(4):738-44. PubMed ID: 26787232
[TBL] [Abstract][Full Text] [Related]
18. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
[TBL] [Abstract][Full Text] [Related]
19. Anisometric Cell and Dysplastic Lipomas in a Retinoblastoma Patient.
den Bakker MA; den Toom DT; Damen THC; Sleddens HFBM; Meijssen IC; Deloose S; Kliffen M; Dinjens WNM
Int J Surg Pathol; 2020 Oct; 28(7):793-798. PubMed ID: 32362169
[TBL] [Abstract][Full Text] [Related]
20. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Mu P; Zhang Z; Benelli M; Karthaus WR; Hoover E; Chen CC; Wongvipat J; Ku SY; Gao D; Cao Z; Shah N; Adams EJ; Abida W; Watson PA; Prandi D; Huang CH; de Stanchina E; Lowe SW; Ellis L; Beltran H; Rubin MA; Goodrich DW; Demichelis F; Sawyers CL
Science; 2017 Jan; 355(6320):84-88. PubMed ID: 28059768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
